Merck Serono Licenses Global Rights to Symphogen’s Sym004 Cancer Antibody Mixture
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)
Published: 26 Sep-2012
DOI: 10.3833/pdr.v2012.i9.1806 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Merck Serono has licensed worldwide rights to develop and commercialise Symphogen’s lead oncology drug candidate Sym004 in a deal potentially worth €495 M (US$622 M)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS